# FDA Approves First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1-Positive Triple-Negative Breast Cancer

> fda · REPORTED · 2026-08-07

The FDA granted approval for the combination of sacituzumab govitecan and pembrolizumab as a first-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), a historically difficult-to-treat subtype with poor prognosis. This approval marks a significant advance in first-line TNBC treatment options and was highlighted by OncLive in its August 7, 2026 weekly news digest.

About Sacituzumab Govitecan + Pembrolizumab (Gilead / Merck): Sacituzumab govitecan is an antibody-drug conjugate targeting Trop-2, developed by Gilead Sciences, and pembrolizumab is a PD-1 checkpoint inhibitor from Merck; the combination targets aggressive triple-negative breast cancer in the first-line metastatic setting.

- Company: Sacituzumab Govitecan + Pembrolizumab (Gilead / Merck)
- Sector: oncology
- Primary source: https://www.onclive.com/clinical/breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.